Astra Faces Off With FDA on Copies of $7 Million-a-Day Drug

  • Prices may drop by 85 percent if generic Crestor is available
  • Court ruling is pending on Astra’s lawsuit to block generics

AstraZeneca Plc is making a final push to protect a drug that makes $7 million a day in the U.S. against cheaper copies as pressure mounts on the U.K. drugmaker to meet its own projections of almost doubling revenue.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.